Critérios de Falência Terapêutica/Prognóstico

Objetivo: Determinar refratariedade à terapêutica com ácido ursodesoxicólico

Scores, variáveis e cálculo:

Qualitative binary definitions	Time (months)	Treatment failure
Rochester [101]	6	ALP $\geqslant 2\times$ ULN or Mayo score $\geqslant 4.5$
Barcelona [62]	12	Decrease in ALP $\leqslant 40\%$ and ALP $\geqslant 1\times$ ULN
Paris-I [63]	12	ALP $\geqslant 3\times$ ULN or AST $\geqslant 2\times$ ULN or bilirubin >1 mg/dl
Rotterdam [102]	12	Bilirubin $\geqslant 1\times$ ULN and/or albumin <1× ULN
Toronto [98]	24	ALP >1.67× ULN
Paris-II [104]	12	ALP $\geqslant 1.5\times$ ULN or AST $\geqslant 1.5\times$ ULN or bilirubin >1 mg/dl
Ehime [103]	6	Decrease in GGT $\leqslant 70\%$ and GGT $\geqslant 1\times$ ULN
Continuous scoring systems	**Time (months)**	**Scoring parameters**
UK-PBC [107]	12	Bilirubin, ALP and AST (or ALT) at 12 mo. Albumin and platelet count at baseline
GLOBE [106]	12	Bilirubin, ALP, albumin, and platelet count at 12 mo. Age at baseline

ALP, alkaline phosphatase; ULN, upper limit of normal; AST, aspartate aminotransferase; GGT, gamma-glutamyltranspeptidase.

Fonte: EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Calculadores automáticos:

GLOBE: http://www.globalpbc.com/globe

UK-PBC http://www.uk-pbc.com/resources/tools/riskcalculator/